Quick Order Cart

Cat. No. ARG27598

IFT22 Knockout HAP1 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone Marrow

  • Disease:

    Chronic myeloid leukemia

IFT22 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout model in near-haploid human cells for studying the small GTPase IFT22, a core component of the intraflagellar transport (IFT) complex A. This product enables loss-of-function analysis of IFT22, which interacts with IFT43, IFT121, and other IFT-A partners to regulate retrograde trafficking and Hedgehog signaling (e.g., SMO, GLI1 activation). Derived from the adherent HAP1 cell line, this polyclonal population is ideal for dissecting ciliogenesis and ciliary signaling defects. It supports applications in immunofluorescence, western blotting, and live-cell imaging for ciliopathy research, functional genomics, and drug screening.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HAP1

    Sex of Donor

    Male

    Age

    40 years

    Derived From Site

    Bone marrow

    Gene Name

    IFT22

    Gene Identifier

    NCBI Gene ID 64792

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    IMDM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

IFT22 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the near-haploid HAP1 cell line, providing a loss-of-function model for the small GTPase IFT22. This polyclonal format enables robust target-gene disruption without clonal isolation, supporting rapid functional screening and pathway analysis in ciliary biology.

The HAP1 host cell line, originating from KBM-7 chronic myeloid leukemia cells, is adherent and fibroblast-like with a near-haploid karyotype ideal for genetic screens. This background facilitates clear interpretation of knockout phenotypes, as single-copy gene disruption unmasks recessive mutations, making it a preferred platform for CRISPR-based functional genomics.

IFT22 is an integral component of the intraflagellar transport (IFT) complex A, essential for retrograde trafficking within primary cilia. It interacts with IFT-A partners IFT43, IFT121, IFT139, and IFT144, as well as IFT70. Upstream regulators include RFX transcription factors and FOXJ1, integrating Hedgehog signaling and cell cycle cues. Downstream, IFT22 mediates retrograde IFT, ciliary disassembly, and Hedgehog pathway output via SMO and GLI1 activation. The knockout disrupts ciliogenesis and interconnected signaling networks involving IFT-B components (IFT88, IFT52), kinesin-2, dynein-2, the BBSome, and transition zone proteins (TCTN1, TMEM216).

In HAP1 cells, IFT22 knockout impairs ciliary assembly and attenuates Hedgehog and Wnt signaling, offering a haploid genetic model to dissect IFT-A function. The polyclonal knockout population is particularly suited for comparing mutant and wild-type phenotypes, facilitating modifier screens and complementation studies. This system helps delineate IFT22??s specific role among IFT-A components, with direct relevance to ciliopathy mechanisms.

Applications include immunofluorescence staining for ciliary markers (acetylated tubulin, ARL13B), western blot analysis of IFT and Hedgehog proteins (GLI1, PTCH1), and RT-qPCR profiling of Hedgehog target genes. Live-cell imaging of IFT dynamics and flow cytometric analysis of ciliated populations are also feasible. This product is suitable for modeling ciliopathies (Joubert syndrome, Meckel syndrome, Bardet-Biedel syndrome), investigating polycystic kidney disease, and screening for therapeutic modulators of ciliary signaling. For further information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)